Egetis Therapeutics AB (publ) Stock: price and insider trades · Sweden

Egetis Therapeutics AB (publ), classified in the Health Care sector, is a listed company. Its insiders report their share dealings to Finansinspektionen. From 18 October 2025 to 18 October 2026, the disclosure feed for Egetis Therapeutics AB (publ) logged 24 filings by 12 insiders.

On the market, 11 insiders bought (18 purchases totalling €47k) while 6 insiders sold (6 sales totalling €585k). The totals do not cover 14 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. On the buying side, the filings list 7 board members, 2 finance chiefs and 2 chief executives among the declarants. Nicklas Westerholm filed the largest sale, €170k, on 15 May 2026, which represents 0.059% of the company's market value.

Across the 890 companies tracked on its exchange, the median is 7 filings; at 24 filings, this issuer sits above that mark. Over the whole record (from 2025), the tally stands at 19 purchases and 6 sales.

In all, 4 purchases were made within 30 days of a purchase by another insider of the company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The last insider purchase was made public on 3 September 2026, 44 days ago. The median gap between a trade and its publication by Finansinspektionen is 3 days. For comparison, MAR article 19 gives managers three business days to notify a trade.

Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. Every figure here comes from the filings published by Finansinspektionen and describes the past, not future prices; it is not investment advice.